However, the co-alteration profiles and TMB were similar in HER2-amplified patients with early- or late-stage NSCLC, providing evidence that HER2 mutations and amplification may induce different lung carcinogenesis procedures. Here, ERBB2 is linked to non-small cell lung carcinoma.